Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GASPAR
2024-516299-13-00Phase 2Completed
- Sponsor
- Centre François Baclesse
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Centre François Baclesse. Primary endpoint: Pathological complete response (pCR) in primary tumour. Started Sep 2024; status: completed.
02
Drugs
spartalizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-516299-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516299-13-00.